Invirsa, Inc., founded in Ohio, is a pharmaceutical company dedicated to enhancing the body's natural defenses to combat infectious diseases and promote wound healing. Their core mission is to develop innovative treatments that augment the body's response to DNA damage, thereby improving cell stability and recovery. Invirsa's lead compound, INV-, is designed to address DNA damage at a critical moment, with a focus on treating ocular conditions and injuries, including those caused by sulfur mustard gas.
Notable affiliations include a significant partnership with BARDA to advance treatments for ocular conditions linked to DNA damage. This collaboration underscores Invirsa's commitment to addressing severe medical needs through cutting-edge science. The company's achievements in developing effective DNA damage control therapies have positioned it as a key player in the pharmaceutical industry, particularly in the realm of wound healing and infectious disease defense.
